Riliprubart Biosimilar Monoclonal Antibody (Complement C1s) for Research

Cat No.: GMP-Bios-INN-1369

Anti-C1S therapeutic antibody (Pre-made Riliprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Riliprubart (development codes BIVV-020/SAR-445088) is a humanized monoclonal antibody targeting complement C1s (C1S). It is developed by True North Therapeutics and Bioverativ and Sanofi and Sanofi-Aventis Recherche & Developpement for Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating polyradiculoneuropathy, Idiopathic thrombocytopenic purpura et al. in Phase III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1369-1mg 1mg 3090
GMP-Bios-INN-1369-10mg 10mg
GMP-Bios-INN-1369-100mg 100mg
GMP-Bios-INN-1369-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Riliprubart biosimilar, Whole mAb, Anti-C1S Antibody: Anti-C1S/Complement C1s subcomponent/C1 esterase/Complement component 1 subcomponent s therapeutic antibody
INN Name Riliprubart
Target C1S
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-III
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2023
Companies True North Therapeutics;Bioverativ; Sanofi;Sanofi-Aventis Recherche & Developpement
Conditions Approved na
Conditions Active Autoimmune haemolytic anaemia;Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Renal transplant rejection
Conditions Discontinued na
Production na
Development Tech na